Imugene This exciting biotech has multiple clinical trial readouts expected in the next 12 months - Stocks Down Under
| IMU Stock | 0.04 0 2.56% |
Slightly above 61% of Imugene's investor base is looking to short. The analysis of the overall investor sentiment regarding Imugene suggests that many traders are alarmed. Imugene's investing sentiment can be driven by a variety of factors including economic data, Imugene's earnings reports, geopolitical events, and overall market trends.
Imugene |
Imugene This exciting biotech has multiple clinical trial readouts expected in the next 12 months Stocks Down Under
Read at news.google.com
 |
Imugene Fundamental Analysis
We analyze Imugene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imugene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imugene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Imugene is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Imugene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Imugene stock to make a market-neutral strategy. Peer analysis of Imugene could also be used in its relative valuation, which is a method of valuing Imugene by comparing valuation metrics with similar companies.
Peers
Imugene Related Equities
| ATM | Aneka Tambang | 4.65 | ||||
| CBA | Commonwealth Bank | 0.64 | ||||
| AN3PI | ANZ Group | 0.47 | ||||
| CBAPG | Commonwealth Bank | 0.44 | ||||
| CBAPM | Commonwealth Bank | 0.15 | ||||
| AN3PJ | ANZ Group | 0.35 | ||||
| CBAPJ | Commonwealth Bank | 0.79 | ||||
| ANZ | Australia | 1.05 |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.